Clayton, Dubilier & Rice announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. Cynosure develops, manufactures, and markets medical aesthetic treatment systems for dermatologists, plastic surgeons, medical spas, and other healthcare practitioners. The company’s broad portfolio of products spans several major categories, including skin revitalization, body contouring, hair removal, and women's health.
“The market for medical aesthetic devices is large and fragmented, with an attractive long-term outlook supported by strong demographic tailwinds, and Cynosure’s business model and channels align well with our extensive experience with similarly positioned consumer-medical device healthcare companies,” says Sandi Peterson, CD&R Partner and soon-to-be chairman of Cynosure’s board of directors. “We believe this business is a great fit with CD&R’s strategy of helping corporate divisions transition to freestanding enterprises and implementing growth and productivity initiatives to accelerate their performance.”
RELATED STORIES
The Cellfina System Receives Five-Year FDA Indication
Galderma Announces Positive Phase 2 Results for its QM1114
Sofwave Medical’s Ultrasound Technology Receives FDA Clearance
